Related Experiment Video

Updated: Nov 11, 2025

Induction and Analysis of Epithelial to Mesenchymal Transition
10:37

Induction and Analysis of Epithelial to Mesenchymal Transition

Published on: August 27, 2013

36.2K

SCARA5 inhibits gastric cancer progression via epithelial-mesenchymal transition suppression

Hangyu Zhang1, Changgang Liu1, Xinbo Wang2

  • 1Department of Diagnostic Pathology, School of Basic Medical Sciences, Weifang Medical University, Shandong Province, China.

Journal of Cancer
|March 24, 2021
PubMed

Insights

Scavenger receptor class A member 5 (SCARA5) is downregulated in gastric cancer (GC), suppressing tumor growth and metastasis. SCARA5 may serve as a diagnostic biomarker and therapeutic target for GC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Scavenger receptor class A member 5 (SCARA5) is implicated in various cancers.
  • The specific roles and mechanisms of SCARA5 in gastric cancer (GC) remain unclear.

Purpose of the Study:

  • To elucidate the biological roles and underlying mechanisms of SCARA5 in gastric cancer.
  • To investigate SCARA5 as a potential diagnostic biomarker and therapeutic target for GC.

Main Methods:

  • Analysis of SCARA5 expression levels in GC tissues and association with promoter methylation.
  • In vitro studies using GC cell lines to assess the effects of SCARA5 overexpression on cell growth, migration, and invasion.
  • In vivo xenograft models to evaluate the impact of SCARA5 upregulation on tumor growth and metastasis.
  • Mechanistic investigations into the pathways affected by SCARA5, including epithelial-mesenchymal transition (EMT) and matrix metalloproteinases (MMPs).

Main Results:

  • SCARA5 expression is downregulated in GC, correlated with promoter methylation.
  • Lower SCARA5 protein levels are associated with aggressive clinicopathological features and poorer prognosis.
  • SCARA5 overexpression inhibited GC cell growth, migration, and invasion in vitro.
  • Upregulation of SCARA5 suppressed tumor growth and metastasis in vivo.
  • SCARA5 suppressed GC cell migration and invasion by inhibiting EMT and inactivating MMP-2 and MMP-9.

Conclusions:

  • SCARA5 plays a crucial role in the genesis and progression of gastric cancer.
  • SCARA5 functions as a tumor suppressor in GC by inhibiting EMT and MMP activity.
  • SCARA5 holds potential as a diagnostic biomarker and therapeutic target for gastric cancer.
Keywords:
EMTGastric cancerSCARA5migration and invasionproliferation

More Related Videos

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

13.7K
Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

9.6K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.8K
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.0K
Role Of Notch Signalling In Intestinal Stem Cell Renewal01:12

Role Of Notch Signalling In Intestinal Stem Cell Renewal

Notch signaling was first discovered in Drosophila melanogaster, where it is involved in cell lineage differentiation. Notch signaling regulates the maintenance and differentiation of intestinal stem cells or ISCs by controlling the expression of atonal homolog 1 or Atoh1. Atoh1 directs cells to differentiate into secretory cells.
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
2.2K